Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells

Author(s):
Wissing, M.D.; Mendonca, J.; Kim, E.; Shim, J.S.; Kaelber, N.S.; Kant, H.; Hammers, H.; Commes, T.; Diest, P.J. van; Liu, J.O.; Kachhap, S.K.
Published
2013
Publication type
Article / Letter to editor
irinotecancetrimonium bromide (CTAB)synthetic lethalityN-myc downstream regulated gene 1 (NDRG1)prostate cancerinvasiontopoisomerase I
Date issued
2013-05-01
Language
English
Is part of
Cancer Biology and Therapy (2013), Vol. 14, no. 5, p. 401-410
hdl
1887/101366
doi
10.4161/cbt.23759